HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.

Abstract
Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of (131)I-labeled monoclonal antibody Mel-14 F(ab')(2) fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab')(2) and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.
AuthorsI Cokgor, G Akabani, H S Friedman, A H Friedman, M R Zalutsky, L M Zehngebot, J M Provenzale, C D Guy, C J Wikstrand, D D Bigner
JournalCancer (Cancer) Vol. 91 Issue 9 Pg. 1809-13 (May 01 2001) ISSN: 0008-543X [Print] United States
PMID11335907 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright 2001 American Cancer Society.
Chemical References
  • Antibodies, Monoclonal
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • L-Selectin
  • Chondroitin Sulfates
Topics
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Chondroitin Sulfates (immunology)
  • Female
  • Humans
  • Iodine Radioisotopes (adverse effects, therapeutic use)
  • L-Selectin (immunology)
  • Melanoma (radiotherapy)
  • Meningitis (etiology)
  • Middle Aged
  • Radiopharmaceuticals (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: